Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Eosera, Inc.
WARNING LETTER
•Eosera, Inc.•January 17, 2020

Eosera, Inc. – FDA Warning Letter, Jan 17, 2020

Record Details

The FDA issued a Warning Letter to Eosera, Inc. following an inspection from January 13-17, 2020, identifying significant CGMP violations for finished pharmaceuticals, rendering their drug products adulterated. The firm manufactures OTC drug products "EAR PAIN MD," "EAR PAIN MD FOR KIDS," and "EAR ITCH MD," which are also cited as unapproved new drugs.

Key violations include: 1. **Inadequate OOS Investigations:** Failure to thoroughly investigate out-of-specification microbial test results for "EAR PAIN MD FOR KIDS" and "EAR PAIN MD" lots, including gram-negative rod contamination and *Burkholderia cepacia*. The firm failed to identify root causes, scope investigations adequately, and implement effective CAPAs. 2. **Deficient Stability Program:** The firm's stability program is inadequate, with unsupported expiry dates, unscientific pH specification changes, and recurring OOS assay results. 3. **Lack of Process Validation:** Failure to validate manufacturing processes for "EAR ITCH MD" and re-validate "EAR PAIN MD" after a facility relocation, indicating a lack of process control. 4. **Inadequate Quality Control Unit:** The Quality Unit lacks adequate procedures, documentation, and authority to ensure CGMP compliance.

The products "EAR PAIN MD," "EAR PAIN MD FOR KIDS," and "EAR ITCH MD" are deemed unapproved new drugs because their

Company
Eosera, Inc.
Inspection date
January 17, 2020
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations II
Person
  • Monica R. Maxwell (Program Division Director)
View Company Profile

ID · 902d53ce-5022-472e-a89f-cfc852ba42df

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121.U.S.C. 355(a)21 U.S.C. 331(d)21 CFR 211.19221 CFR 211.166(a)21 CFR 211.100(a)21 CFR 211.22(a)21 CFR 211.22(d)

Full citation text and observation details available on the Dashboard.

Other documents for Eosera, Inc.
  • 483 - 2026-03-20March 20, 2026
  • 483 - 2025-04-28April 28, 2025
  • 483 - 2020-01-17January 17, 2020

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Eosera, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.